NVS vs OMDA
Novartis AG vs Omada Health — AI-powered side-by-side comparison
| Metric | NVS | OMDA |
|---|
| AI Score |
75
|
59
|
| Price |
$154.64
|
$24.00
|
| P/E Ratio |
23.55×
|
353.61×
|
| ROE |
30.5%
|
-5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
68.2%
|
| Debt / Equity |
1.18×
|
0.00×
|
| Dividend Yield |
2.9%
|
0.0%
|
| RSI (14) |
57.7
|
66.6
|
| Beta |
0.462
|
1.7204
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus OMDA.
NVS leads by 16 points.
NVS scores 75/100 (Buy) versus OMDA at 59/100 (Buy).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
OMDA Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 35.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Bollinger bandwidth of 35.5% signals elevated volatility — Risk